Scholar Rock Holding Corporation
SRRKHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeScholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating. The company carries a $6.74B market cap, placing it firmly in the mid-cap category. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Market Cap
$6.74B
Beta
0.68
P/E (TTM)
—
P/E (Fwd)
-23.76
EPS (TTM)
$-3.31
EPS (Fwd)
$-2.33
ROE
-167.8%
ROA
-58.8%
Cash
$492.1M
Total Debt
$203.8M
Free CF
-$153.9M
52W Change
75.2%
Annual Financials
Cash vs Debt
Where SRRK stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SRRK finished 14.79% above its 150-day moving average ($48.87) and 18.01% above its 200-day moving average ($47.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SRRK overbought or oversold?
At the September 3, 2026 close, SRRK's RSI(14) was 59.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $492.1M in cash comfortably exceeding the $203.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$153.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -167.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $18.8M (2021) to $0 (2025), a 100% decline worth watching.
SRRK's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, SRRK has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SRRK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.